Furthermore, reductions in NT-proBNP levels after initiating PAH-targeted therapies are associated with improved exercise capacity, hemodynamics, and survival, underscoring its value as a surrogate treatment response marker. Here, NPPB is linked to pulmonary arterial hypertension.